Intercept Pharmaceuticals Company
Intercept Pharmaceuticals develops small molecule drugs and therapeutics for the treatment of chronic fibrotic and metabolic diseases.
Funding Status:
IPO
Headquarters:
United States
Industry:
Metabolism Dysfunctions
Estimated Revenue:
$50M to $100M
Technology:
Cancer
Employee Number:
501-1000
Founded Date:
2002